BioCentury | Jun 16, 2014
Strategy

Nucleotide arms race

The acquisition of Idenix Pharmaceuticals Inc. will fill a hole in Merck & Co. Inc. 's HCV toolbox and give the pharma a chance to develop an interferon-free regimen that can treat all patients at...
BC Week In Review | Jun 17, 2013
Company News

Gilead, Roche infectious news

Gilead disclosed in an SEC filing that it submitted in April a response to arbitration initiated by Roche alleging the pharma has an exclusive license to sofosbuvir under a 2004 deal between Roche's Hoffman-La Roche...
BioCentury | Oct 22, 2012
Product Development

Nuclear pacifism

Phase IIb data released by Abbott Laboratories last week provide the most compelling argument to date that all-oral HCV cocktails do not require a nucleotide-based NS5B inhibitor. An abstract released ahead of the American Association...
BC Week In Review | Apr 9, 2012
Clinical News

Danoprevir: Phase IIb data

The double-blind, international Phase IIb INFORM-SVR trial in 169 treatment-naive patients with HCV genotype 1 infection showed that 41% of 63 evaluable patients who received twice-daily oral mericitabine , danoprevir and ritonavir, plus ribavirin for 24...
BC Week In Review | Apr 9, 2012
Clinical News

Mericitabine: Phase IIb data

The double-blind, international Phase IIb INFORM-SVR trial in 169 treatment-naive patients with HCV genotype 1 infection showed that 41% of 63 evaluable patients who received twice-daily oral mericitabine, danoprevir and ritonavir, plus ribavirin for 24...
BC Extra | Apr 5, 2012
Clinical News

Abstract unveils SVR data for Roche interferon-free regimen

A 24-week, interferon-free HCV regimen containing two Roche (SIX:ROG; OTCQX:RHHBY) compounds led to a sustained virologic response (SVR) eight weeks after the end of treatment in 26 (41%) of 63 evaluable patients in one arm...
BC Innovations | Jan 12, 2012
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV NS5B polymerase In vitro and animal studies identified indole-based NS5B polymerase inhibitors that could treat HCV infection. Chemical synthesis, in vitro testing...
BC Week In Review | Jan 2, 2012
Clinical News

Victrelis boceprevir: Phase II started

Merck began the international Phase II DYNAMO 1 trial to evaluate Victrelis boceprevir plus mericitabine and standard of care (SOC, Pegasys pegylated interferon alfa-2a and Copegus ribavirin) in about 25 patients with a null response...
BC Week In Review | Dec 5, 2011
Company News

Gilead, Pharmasset deal

Gilead will acquire HCV company Pharmasset for $137 per share in cash. The price is an 89% premium to Pharmasset's close of $72.67 on Nov. 18, before the deal was announced, and values Pharmasset at...
BC Extra | Nov 22, 2011
Top Story

Gilead to acquire Pharmasset for $11B

Gilead Sciences Inc. (NASDAQ:GILD) will acquire HCV company Pharmasset Inc. (NASDAQ:VRUS) for $137 per share in cash. The price is an 89% premium to Pharmasset's close of $72.67 on Friday, before the deal was announced,...
Items per page:
1 - 10 of 90